23 June 2019: Articles
Unclassified Vasculitis with Episcleritis, Thrombophlebitis, Deep Vein Thrombosis, Pulmonary Vasculitis, and Intracranial Vasculitis: An Autopsy Case Report
Challenging differential diagnosis, Rare disease
Eri Watanabe ABCDEF 1*, Akira Tanaka BDE 2, Hitoshi Sugawara ADE 3, Kumiko Nishina B 1,4, Hiroki Yabe B 1, Takahisa Gono BE 1, Chihiro Terai B 1DOI: 10.12659/AJCR.915527
Am J Case Rep 2019; 20:886-895
Abstract
BACKGROUND: Systemic vasculitides constitute heterogenous conditions affecting many organs and systems through blood vessel inflammation. Although there are some classifications for vasculitis, several vasculitides are “unclassified” because they cannot be clearly assigned to one of the known entities.
CASE REPORT: We report an autopsy case of a 67-year-old Japanese man who presented with fever, ocular pain, erythema, chest pain, and headache. The disease caused episcleritis, thrombophlebitis, extensive deep vein thrombosis, multiple pulmonary nodules and masses, hypertrophic pachymeningitis, and hyper-intensity areas in brain parenchyma on magnetic resonance images. Histopathology of the pulmonary nodule confirmed vasculitis affecting medium-to-small veins and arteries without necrotizing vasculitis or granulomatous inflammation. We diagnosed the patient with unclassified vasculitis based on the clinicopathological characteristics. Steroids in combination with immunosuppressants were used, but the disease was refractory and relapsing. The disease activity was eventually controlled with rituximab, but the patient died of bronchopneumonia. On autopsy, lung and brain findings indicated healed vascular inflammation.
CONCLUSIONS: This is the first case report of unclassified vasculitis, which is characterized as medium-to-small-sized arteritis and phlebitis, causing episcleritis, thrombophlebitis, deep vein thrombosis, pulmonary vasculitis, and intracranial vasculitis. The clinical conditions share some similarities with granulomatosis with polyangiitis and Behçet’s disease; however, they meet no classification criteria of any specific vasculitis. More cases need to be analyzed to confirm our findings.
Keywords: Arthritis, Multiple Pulmonary Nodules, Phlebitis, Relapsing Fever, Vasculitis, Vasculitis, Central Nervous System, Autopsy, Fatal Outcome, Scleritis, Thrombophlebitis, Venous Thrombosis
Background
Systemic vasculitides constitute heterogenous conditions affecting many organs and systems through blood vessel inflammation. The etiology and pathogenesis of vasculitides are not completely understood. The Chapel Hill Consensus Conference (CHCC) in 1994 designated definitions for vasculitis, and 10 systemic vasculitides were defined according to clinical and pathological features [1]. The definitions were revised by the CHCC in 2012, and 7 categories and 26 diseases were defined [2]. However, several vasculitides remained “unclassified” because: 1. they were not included in the CHCC definitions (e.g., antiphospholipid antibody syndrome, Buerger disease, and Eale’s disease), 2. the relationship between vasculitis and other manifestations remains unclear (e.g., IgG4-related disease and chronic periaortitis), and 3. the vasculitis cannot be clearly assigned to one of the known entities (e.g., vasculitis characterized by acral necrosis or granulomatous giant cell polyphlebitis) [3]. For the third reason, these vasculitides are termed “unclassified vasculitis” or “undifferentiated vasculitis”, but their nomenclature is not clearly defined.
We report the first case of unclassified vasculitis, which is characterized as medium-to-small-sized arteritis and phlebitis, causing relapsing fever, episcleritis, thrombophlebitis, deep vein thrombosis (DVT), pulmonary vasculitis, and intracranial vasculitis. We discuss the case with histopathological investigation of the antemortem biopsy and autopsy findings.
Case Report
A 67-year-old Japanese man was admitted to our hospital with fever and severe headache. He had no significant medical or family history. Eight years prior, he was admitted to our hospital with fever, headache, ocular pain, and erythema nodosum-like rash on the extremities. Laboratory data demonstrated marked inflammation [white blood cell count, 9880/μL; C-reactive protein (CRP), 19.5 mg/dL]. The ocular condition was diagnosed as episcleritis (Figure 1A), and skin biopsy of erythema revealed thrombophlebitis (Figure 1B). Hyper-intense areas at the globus pallidus were noted by head magnetic resonance imaging (MRI) on T2-weighted images (T2WI) (Figure 1C). The patient was first suspected to have neuro-Behçet’s disease (NBD) because of the intracranial lesion and thrombophlebitis; however, the diagnostic criteria for Behçet’s disease (BD) [4,5] were not satisfied because of the lack of oral aphthosis, genital ulcer, and uveitis, and negative pathergy test. The human leukocyte antigen test was positive for A23, A33, B39, B44, DR4, and DR13, which are not risk factors of BD [6]. He was next suspected to have small-vessel vasculitis, such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis, because of the complication of episcleritis; however, proteinase 3-anti-neutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA were negative, and no other evidence supported these diagnoses. We tentatively diagnosed him with unclassified vasculitis. After initiation of intravenous methylprednisolone (mPSL) pulse therapy (1000 mg/day of mPSL for 3 days) followed by 1 mg/kg/day of prednisolone (PSL), all symptoms and inflammatory markers immediately improved. However, he repeatedly relapsed with fever, headache, episcleritis, and erythema after PSL was tapered to under 15 mg/day. Azathioprine and colchicine were added, but these did not inhibit palindromic flare. Gene analysis was performed to investigate autoinflammatory disease. Heterozygosity for the E148Q mutation in the
Six years prior to the current hospitalization, the patient was readmitted to our hospital because of fever and new-onset chest pain with inflammatory markers. Computed tomography (CT) revealed multiple pulmonary nodules (Figure 2A–2D), and he underwent biopsy of the nodule in the right S6 by video-assisted thoracic surgery. The biopsy specimen exhibited vasculitis in both arteries and veins, which were predominantly infiltrated by lymphocytes and plasmacytes (Figure 3A–3H). The size of the affected vessels was medium-to-small, and capillaritis was not detected. Intra-alveolar fibrosis with infiltration of lymphocytes and plasmacytes was also observed (Figure 3F–3H). Typical pathological manifestations of GPA, such as necrotizing vasculitis and granulomatous lesions [11], were not found. These pathological findings did not meet any existing classification criteria for specific vasculitides. The clinical findings also did not meet the criteria for GPA [12] or any other diagnostic criteria for vasculitis, including the CHCC definitions [1,2]. We decided to treat the unclassified vasculitis with PSL at 1 mg/kg/day in combination with biweekly intravenous cyclophosphamide (IVCY) at 500 mg for 6 courses. The pulmonary nodules and inflammatory markers immediately improved with the combination therapy. However, the patient had repeated relapses of fever, headache, and multiple pulmonary nodules whenever the IVCY course finished. Sufficient doses of methotrexate, cyclosporine, and infliximab were each administered as alternate immunosuppressants for cyclophosphamide, but they were ineffective.
One year prior to the current hospitalization, the patient developed extensive DVT. Thrombosis extended from the inferior vena cava to the left femoral vein with inflammatory markers (CRP, 30.6 mg/dL). Antiphospholipid antibodies were negative, and no other thrombotic predisposition was noted, so we suspected that the DVT was caused by phlebitis associated with his unclassified vasculitis. We restarted biweekly IVCY at 500 mg for 6 courses with anticoagulation therapy, and satisfactory responses were observed with these therapies.
Two weeks prior to the current hospitalization, severe headache and chest pain relapsed. Chest radiography and CT revealed a large pulmonary mass in the right S1 (Figure 4A, 4B). The patient was readmitted for further investigation. Laboratory data on admission indicated normocytic normochromic anemia with hemoglobin at 8.9 g/dL and elevated CRP levels at 14.7 mg/dL, and he was negative for rheumatoid factor and antinuclear antibody. Cytoplasmic ANCA and perinuclear ANCA were not detected by immunofluorescence assay. Proteinase 3-ANCA and myeloperoxidase-ANCA were also negative by ELISA. Regarding infection, interferon-gamma release assays and β-D-glucan were negative, and blood and sputum cultures were negative for bacteria, mycobacteria, and fungi. Bronchoscopy with bronchoalveolar lavage and brushing cytology for the right S1were performed, and no microorganism or neoplastic cells were detected. Thus, we suspected that the pulmonary mass was associated with his unclassified vasculitis.
For investigation of severe headache, gadolinium-enhanced brain MRI was performed. Hypertrophic pachymeningitis (HP) and a ring-enhancing lesion with central hyper-intensity on diffusion-weighted images (DWI) were observed (Figure 5A–5C). Two weeks later, MRI revealed multiple patchy hyper-intense areas on T2WI, fluid-attenuated inversion recovery (FLAIR), DWI, and gadolinium-enhanced T1-weighted images (Gad-T1WI) (Figure 5D–5F). Cerebrospinal fluid (CSF) examination demonstrated normal cytology, negative immunoglobulin G (IgG) index (0.48), and high interleukin (IL)-6 levels (14.4 pg/mL), which excluded demyelinating disorders such as multiple sclerosis. The CSF culture was sterile, and no neoplastic cells were detected. We suspected that these intracranial lesions were also caused by the underlying unclassified vasculitis, and PSL at 1.5 mg/kg/day was administered.
Two weeks after receiving PSL at 1.5 mg/kg/day, the patient rapidly developed respiratory failure with fever and elevated CRP levels. Chest CT revealed nodules and masses with slight consolidation at the bilateral S6–10 (Figure 6A, 6B). Bronchoalveolar lavage revealed no evidence of alveolar hemorrhage or pneumonia (bacterial, pneumocystis, fungus, and mycobacterium). We suspected that the pulmonary masses were associated with his unclassified vasculitis and administered mPSL pulse. His respiratory condition and the pulmonary mass and nodule immediately improved after the treatment. However, the effects of the mPSL pulse were temporary, and multiple pulmonary nodules and masses with respiratory failure repeatedly relapsed. We initiated rituximab (RTX) at 375 mg/m2/week as an additional immunosuppressant, which is widely used to treat vasculitides, particularly ANCA-associated vasculitis [13–15]. RTX was immediately effective for his presenting symptoms, including the multiple pulmonary nodules and masses with respiratory failure, headache, and elevated CRP levels. Therefore, RTX was continued and PSL was tapered gradually.
After the third course of RTX, fever and respiratory failure without pulmonary nodules developed. Pneumonia was suspected and antibiotics were administered, but the patient died on the 155th hospital day.
An autopsy was conducted to identify the cause of death and clarify the diagnosis of unclassified vasculitis. Pathological findings of the lungs revealed no vasculitis, but intimal hypertrophy and adventitial fibrosis remained in some parts (Figure 7A–7D). Age-related vasculopathy-like changes were not shown in either normal vessels or in vessels which had intimal hypertrophy and adventitial fibrosis. Bronchopneumonia was the major finding of the lungs, which exhibited neutrophil and macrophage infiltration into the peripheral bronchi and alveolar spaces on culture of the lung tissue (
The clinicohistopathological findings for the patient’s vasculitis were as follows: antemortem biopsy findings of thrombophlebitis and pulmonary vasculitis affecting both veins and arteries of medium-to-small-sized vessels without necrotizing vasculitis or granulomatous inflammation; autopsy findings of intracranial vasculitis (HP and small necrotic foci with gliosis in brain parenchyma); and clinical findings of episcleritis and extensive DVT. Thus, we concluded that the patient had a previously unreported type of unclassified vasculitis.
Discussion
This is the first case report of unclassified vasculitis characterized by medium-to-small-sized arteritis and phlebitis, causing relapsing fever, episcleritis, thrombophlebitis, DVT, pulmonary vasculitis, and intracranial vasculitis. The clinical conditions share some similarities with GPA and BD; however, they were not sufficient to diagnose GPA or BD, nor any specific vasculitis (Table 1). Next, we discuss the 3 initial characteristic points in our case considering the differential diagnosis: 1. presenting pulmonary vasculitis with multiple nodules and masses, 2. presenting intracranial vasculitis with HP and cerebral lesions, and 3. affecting arteries and veins.
First, pulmonary manifestations were an individual finding in our case. GPA was primarily considered as the differential diagnosis because GPA is the most common cause of pulmonary nodules and masses in noninfectious inflammatory conditions. In GPA, up to 90% of radiographic abnormalities seen at presentation are pulmonary nodules and masses [16], and up to 65% of patients have multiple nodules, but they can be solitary [17]. The nodules and masses of GPA can range from a few millimeters to >10 cm in diameter [16]. Pathologically, the nodules and masses in GPA are composed of vasculitis, parenchymal necrosis, or granulomatous inflammation [11,18]. In our case, the clinical presentation of pulmonary nodules and masses resembled that of GPA; however, the diagnostic criteria for GPA were not satisfied [12], as the pathology of the antemortem biopsy of the lung was inconsistent with GPA. Vasculitis affecting medium-to-small veins and arteries without necrotizing vasculitis or granulomatous inflammation has never been reported. Moreover, the findings of fibrosis with lymphocyte and plasmacyte infiltration in the pulmonary alveoli were inconsistent with GPA. This intra-alveolar finding mimicked histologically lymphoplasmacytic-type inflammatory pseudotumors [19] caused by IgG4-related disease [20]; however, the serum IgG4 levels were not elevated, and no IgG4-positive plasmacyte infiltration was noted by immunostaining.
The second characteristic finding in our case was intracranial vasculitis with HP and cerebral lesions. NBD was considered as a differential diagnosis according to head MRI manifestations and pathological findings on autopsy. NBD is subcategorized into parenchymal NBD (P-NBD) and nonparenchymal NBD (NP-NBD) types[21]. Furthermore, P-NBD is subdivided into acute P-NBD (A-P-NBD) and chronic progressive P-NBD (CP-P-NBD) [22,23]. A-P-NBD is characterized by acute meningoencephalitis with or without focal lesions. MRI of the focal lesions demonstrates hyper-intensity on DWI and T2WI, and the lesions are commonly enhanced on Gad-T1WI [21]. CP-PNBD is characterized by slowly progressive dementia and ataxia with persistent elevation of CSF IL-6 (≥20 pg/mL), and progressive brainstem atrophy on MRI [21–24]. The brain pathology in A-P-NBD is perivasculitis characterized by perivascular infiltration of lymphocytes and neutrophils with or without signs of necrosis. In later stages, inflammatory infiltration is less prominent, and axonal loss and gliosis predominate [21,25]. In our case, histopathological findings of small necrotic foci with gliosis met the criteria for NBD. Furthermore, A-P-NBD is more likely than CP-P-NBD because of the CSF IL-6 levels (14.4 pg/mL) and the absence of brainstem atrophy. Varying patterns were observed on MRI throughout the patient history: (a) hyper-intensity on T2WI at the globus pallidus, (b) ring-enhancing lesion with central hyper-intensity on DWI, and (c) multiple patchy hyper-intense areas on DWI, T2WI, FLAIR, and Gad-T1WI. The findings of (a) and (c) correspond to the presentation of A-P-NBD, whereas those of (b) may correspond to NBD, as some case reports described NBD causing ring-enhancing lesions [26–29]. Nishino et al. reported that GPA can cause cerebritis, but it is rare among the other neurological manifestations in GPA (approximately 4%) [30]. MRI manifestations of cerebritis in GPA are reported as DWI restriction and patchy high T2 signals [31], but HP is a rare condition in NPNBD [21,32]; however, a case report described HP in NBD, suggesting an association [33].
The third characteristic point was that the patient’s vasculitis was not only arteritis but also phlebitis presented as thrombophlebitis, DVT, and pulmonary vasculitis. Vasculitis with no predominant type of vessel involved that can affect vessels of any size and type (arteries, veins, and capillaries) is included in the category of “variable vessel vasculitis” in the CHCC definitions, which comprises only BD and Cogan’s syndrome [2]. Thrombophlebitis and extensive DVT are common in BD, but the pulmonary presentation does not correspond to BD, and the diagnostic criteria for BD [4,5] were not satisfied. Cogan’s syndrome was also excluded because audiovestibular symptoms were not present [34,35].
The limitation of our approach and conclusions is that evidence from autopsy samples supporting vasculitis remained insufficient because the active phase had already passed when the autopsy was performed. Antemortem biopsies of brain parenchyma were not performed because the patient’s condition prevented invasive study; therefore, consistency between the autopsy and antemortem status cannot be confirmed. The autopsy of the lungs was consistent with the antemortem biopsies because the autopsy findings of intimal hypertrophy and adventitial fibrosis in the arteries were considered to be healed vasculitis. According to our observations, more cases should be analyzed to clarify the characteristics of the disease.
Conclusions
This is the first case report of an unclassified vasculitis, which was characterized by medium-to-small-sized arteritis and phlebitis without necrotizing vasculitis or granulomatous inflammation, causing relapsing fever, episcleritis, thrombophlebitis, DVT, pulmonary vasculitis, and intracranial vasculitis. The clinical conditions share some similarities with GPA and BD; however, no classification criteria for any specific vasculitis were met. More cases need to be analyzed to confirm our findings.
References:
1.. Jennette JC, Falk RJ, Andrassy K, Nomenclature of systemic vasculitides. Proposal of an international consensus conference: Arthritis Rheum, 1994; 37; 187-92, pmid: 8129773
2.. Jennette JC, Falk RJ, Bacon PA, 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: Arthritis Rheum, 2013; 65; 1-11, pmid: 23045170
3.. Lamprecht P, Pipitone N, Gross WL, Unclassified vasculitis: Clin Exp Rheumatol, 2011; 29(1 Suppl. 64); S81-85
4.. , Criteria for diagnosis of Behçet’s disease: Lancet, 1990; 335; 1078-80, pmid: 1970380
5.. Davatchi F, Assaad-Khalil S, Calamia KT, The International Criteria for Behçet’s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria: J Eur Acad Dermatology Venereol, 2014; 28; 338-47
6.. Ombrello MJ, Kirino Y, de Bakker PI, Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity: Proc Natl Acad Sci USA, 2014; 111; 8867-72, pmid: 24821759
7.. Tchernitchko D, Legendre M, Cazeneuve C, The E148QMEFV allele is not implicated in the development of familial Mediterranean fever: Hum Mutat, 2003; 22; 339-40
8.. Ben-Chetrit E, Lerer I, Malamud E, The E148Q mutation in the MEFV gene: Is it a disease-causing mutation or a sequence variant?: Hum Mutat, 2000; 15; 385-86
9.. Livneh A, Langevitz P, Zemer D, Criteria for the diagnosis of familial mediterranean fever: Arthritis Rheum, 1997; 40; 1879-85, pmid: 9336425
10.. McDermott MF, Aksentijevich I, Galon J, Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes: Cell, 1999; 97; 133-44, pmid: 10199409
11.. Travis WD, Colby TV, Koss MN: Non-neoplastic disorders of the lower respiratory tract (AFIP Atlas of Nontumor Pathology series Vol. 2), 2002; 234-44, Washington, DC, American Registry of Pathology and the Armed Forces Institute of Pathology
12.. Leavitt RY, Fauci AS, Bloch DA, The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis: Arthritis Rheum, 1990; 33; 1101-7, pmid: 2202308
13.. Hassan RI, Gaffo AL, Rituximab in ANCA-associated vasculitis: Curr Rheumatol Rep, 2017; 19; 6, pmid: 28155022
14.. Rees F, Yazdani R, Lanyon P, Long-term follow-up of different refractory systemic vasculitides treated with rituximab: Clin Rheumatol, 2011; 30; 1241-45, pmid: 21523362
15.. Watts RA, Scott DG, Vasculitis and inflammatory arthritis: Best Pract Res Clin Rheumatol, 2016; 30; 916-31, pmid: 27964796
16.. Castañer E, Alguersuari A, Andreu M, Imaging findings in pulmonary vasculitis: Semin Ultrasound CT MRI, 2012; 33; 567-79
17.. Flores-Suárez LF, Alba MA, Mateos-Toledo H, Ruiz N, Pulmonary involvement in systemic vasculitis: Curr Rheumatol Rep, 2017; 19; 56, pmid: 28752492
18.. Chung MP, Yi CA, Lee HY, Imaging of pulmonary vasculitis: Radiology, 2010; 255; 322-41, pmid: 20413748
19.. Matsubara O, Tan-Liu NS, Kenney RM, Mark EJ, Inflammatory pseudotumors of the lung: progression from organizing pneumonia to fibrous histiocytoma or to plasma cell granuloma in 32 cases: Hum Pathol, 1988; 19; 807-14, pmid: 2841219
20.. Zen Y, Kitagawa S, Minato H, IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung: Hum Pathol, 2005; 36; 710-17, pmid: 16084938
21.. Kalra S, Silman A, Akman-Demir G, Diagnosis and management of Neuro-Behçet’s disease: International consensus recommendations: J Neurol, 2014; 261; 1662-76, pmid: 24366648
22.. Hirohata S, Kikuchi H, Sawada T, Clinical characteristics of neuro-Behcet’s disease in Japan: A multicenter retrospective analysis: Mod Rheumatol, 2012; 22; 405-13, pmid: 21935641
23.. Ishido M, Horita N, Takeuchi M, Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: Meta-analysis: Sci Rep, 2017; 7; 10196, pmid: 28860590
24.. Hirohata S, Isshi K, Oguchi H, Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet’s syndrome: Clin Immunol Immunopathol, 1997; 82; 12-17, pmid: 9000037
25.. Hirohata S, Histopathology of central nervous system lesions in Behçet’s disease: J Neurol Sci, 2008; 267; 41-47, pmid: 17976652
26.. Yasuda C, Okada K, Takechi U, Tsuji S, Ring-enhanced brainstem lesion in a patient with neuro-Behcet’s disease: Intern Med, 2012; 51; 991-92, pmid: 22504269
27.. Heo JH, Lee ST, Chu K, Kim M, Neuro-Behcet’s disease mimicking multiple brain tumors: Diffusion-weighted MR study and literature review: J Neurol Sci, 2008; 264; 177-81, pmid: 17850821
28.. Imoto H, Nishizaki T, Nogami K, Neuro-Behçet’s disease manifesting as a neoplasm-like lesion – case report: Neurol Med Chir (Tokyo), 2002; 42; 406-9, pmid: 12371599
29.. Kuriwaka R, Kunishige M, Nakahira H, Neuro-Behçet’s disease with chorea after remission of intestinal Behçet’s disease: Clin Rheumatol, 2004; 23; 364-67, pmid: 15293103
30.. Nishino H, Rubino FA, DeRemee RA, Neurological involvement in Wegener’s granulomatosis: An analysis of 324 consecutive patients at the Mayo Clinic: Ann Neurol, 1993; 33; 4-9, pmid: 8388187
31.. Pakalniskis MG, Berg AD, Policeni BA, The many faces of granulomatosis with polyangiitis: A review of the head and neck imaging manifestations: Am J Roentgenol, 2015; 205; W619-29, pmid: 26587951
32.. Al-Araji A, Kidd DP, Neuro-Behçet’s disease: Epidemiology, clinical characteristics, and management: Lancet Neurol, 2009; 8; 192-204, pmid: 19161910
33.. Yoon BN, Kim SJ, Lim MJ, Neuro-Behçet’s disease presenting as hypertrophic pachymeningitis: Exp Neurobiol, 2015; 24; 252-55, pmid: 26412975
34.. Cogan DG, Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms: Arch Ophthalmol, 1945; 33; 144-49
35.. Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS, Cogan syndrome: Studies in thirteen patients, long-term follow-up, and a review of the literature: Medicine, 1980; 59; 426-41, pmid: 6969345
36.. Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA, Venous thromboembolism in ANCA-associated vasculitis – incidence and risk factors: Rheumatology, 2007; 47; 530-34
37.. Ungprasert P, Koster MJ, Thongprayoon C, Warrington KJ, Risk of venous thromboembolism among patients with vasculitis: A systematic review and meta-analysis: Clin Rheumatol, 2016; 35; 2741-47, pmid: 27572522
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






